Sonelokimab

Modify Date: 2024-01-03 16:18:53

Sonelokimab structure	Common Name	Sonelokimab
	CAS Number	1414386-05-2	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Sonelokimab

Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin VHHs. Sonelokimab has the potential for plaque-type psoriasis research[1][2].

Name	Sonelokimab

Description	Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin VHHs. Sonelokimab has the potential for plaque-type psoriasis research[1][2].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
Target	IL-17A IL-17F
References	[1]. Kim A Papp, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021 Apr 24;397(10284):1564-1575. [2]. Martin A Rossotti, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289(14):4304-4327.

No Any Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Sonelokimab

Use of Sonelokimab

Names

Sonelokimab Biological Activity

Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.